Hyundai Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hyundai Pharmaceutical makes prescription drugs, over-the-counter medicines, functional foods, and cosmetics, ranging from treatments for dementia and abnormal cholesterol levels to a well-known hair-loss remedy and a dietary-fibre drink.
It supplies hospitals, clinics, pharmacies, and wholesalers across South Korea, and is listed on KOSPI, Korea's main stock exchange. Its business spans four distinct segments, pharmaceuticals, food, cosmetics, and medical devices, with the food segment anchored by a single long-running dietary-fibre beverage brand.
Summary is AI-generated and may contain errors · figures from DART filings
The company entered the cosmetics business using in-house peptide and compound-ingredient technology developed through its own pharmaceutical research capabilities.
Hyundai Pharmaceutical in five facts
What does Hyundai Pharmaceutical do?
Hyundai Pharmaceutical makes prescription drugs, over-the-counter medicines, functional foods, and cosmetics, ranging from treatments for dementia and abnormal cholesterol levels to a well-known hair-loss remedy and a dietary-fibre drink.
Where is Hyundai Pharmaceutical listed and in which sector?
Hyundai Pharmaceutical (Korean name: 현대약품) trades under KRX code 004310 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hyundai Pharmaceutical?
Its market capitalisation was US$182.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hyundai Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Hyundai Pharmaceutical reported revenue of US$144.8M, operating profit of US$3.1M and net income of US$1.9M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was up 9.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Quarterly report (2026.08)Oct 15
- Decision to acquire shares/equity in another company
Hyundai Pharmaceutical disclosed an acquisition of an individual, worth US$7.55M.
M&A · Feb 27 - Material event report (equity acquisition)M&A · Feb 27
- Treasury share disposal: results reportTreasury Shares · Feb 27
- [Amended] Material event report (treasury share disposal)
Hyundai Pharmaceutical updated a disclosed plan to sell treasury shares worth US$42.8M, about 23.2% of its market value.
Treasury Shares · Feb 27 · 2 versions - Cash/in-kind dividend decision
Hyundai Pharmaceutical declared a cash dividend of US$0.02 per share.
Dividend · Feb 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 5